
Royalty Pharma PLC
NASDAQ:RPRX

Intrinsic Value
The intrinsic value of one
RPRX
stock under the Base Case scenario is
65.185
USD.
Compared to the current market price of 34.005 USD,
Royalty Pharma PLC
is
Undervalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Royalty Pharma PLC
Fundamental Analysis

Royalty Pharma’s core revenue streams are highly exposed to patent cliffs on its top-selling therapies, creating potential for steep revenue declines if pipeline replacements fail to materialize in time.
Royalty Pharma’s diversified portfolio of royalties across multiple blockbuster therapies shields it from the volatility typically associated with single-drug exposure, supporting robust cash flows.

Revenue & Expenses Breakdown
Royalty Pharma PLC
Balance Sheet Decomposition
Royalty Pharma PLC
Current Assets | 1.8B |
Cash & Short-Term Investments | 1.8B |
Receivables | 23.8m |
Other Current Assets | 3.1m |
Non-Current Assets | 15.8B |
Long-Term Investments | 15.7B |
Other Non-Current Assets | 36.7m |
Free Cash Flow Analysis
Royalty Pharma PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Royalty Pharma PLC
Revenue
|
2.3B
USD
|
Operating Expenses
|
-363.4m
USD
|
Operating Income
|
1.9B
USD
|
Other Expenses
|
-807.8m
USD
|
Net Income
|
1.1B
USD
|
RPRX Profitability Score
Profitability Due Diligence
Royalty Pharma PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Score
Royalty Pharma PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
RPRX Solvency Score
Solvency Due Diligence
Royalty Pharma PLC's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Score
Royalty Pharma PLC's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 41.764 USD
with a low forecast of 35.017 USD and a high forecast of 53.55 USD.
Dividends
Current shareholder yield for RPRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RPRX
stock under the Base Case scenario is
65.185
USD.
Compared to the current market price of 34.005 USD,
Royalty Pharma PLC
is
Undervalued by 48%.